NCT05734404 is a clinical trial in Central Nervous System Vasculitis, sponsored by University of Pennsylvania.

Who is sponsoring NCT05734404?

NCT05734404 is sponsored by University of Pennsylvania.

What condition does NCT05734404 study?

NCT05734404 studies Central Nervous System Vasculitis, CNS Vasculitis, CNSV, Vasculitis.

Is NCT05734404 still recruiting?

NCT05734404 is currently recruiting now. Last updated 23 January 2026.

Last reviewed 2026-01-23 · How we verify

NCT05734404

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Longitudinal Study for Central Nervous System Vasculitis

Recruiting now Last updated 23 January 2026

What this trial tests

trial in Central Nervous System Vasculitis in 40 participants. Currently enrolling.

Timeline

1 March 2023

Primary endpoint
31 December 2030

31 December 2030

Quick facts

Lead sponsor	University of Pennsylvania
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	40
Start date	1 March 2023
Primary completion	31 December 2030
Estimated completion	31 December 2030
Sites	6 locations across Canada, United States

Conditions studied

Central Nervous System Vasculitis — all drugs for Central Nervous System Vasculitis →
CNS Vasculitis — all drugs for CNS Vasculitis →
CNSV — all drugs for CNSV →
Vasculitis — all drugs for Vasculitis →

Sponsor

University of Pennsylvania

Who can join

18 and older, any sex, with Central Nervous System Vasculitis or CNS Vasculitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Primary central nervous system vasculitis (CNSV) is a potentially fatal, single-organ vasculitis that often involves a spectrum of neurologic complications, including strokes, cognitive and speech impairment, visual loss, dementia, and encephalopathy. The purpose of this study is to establish a research cohort to investigate the disease process, treatments, and patient outcomes in CNSV.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University of Pennsylvania trials

Trials by the same sponsor.

NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05734404 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
Last refreshed: 23 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05734404.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing